Roth Capital Issues Negative Estimate for biote Earnings

biote Corp. (NASDAQ:BTMD) – Investment analysts at Roth Capital cut their Q1 2025 earnings estimates for shares of biote in a report issued on Thursday, March 13th. Roth Capital analyst G. Kelly now expects that the company will post earnings per share of $0.09 for the quarter, down from their prior forecast of $0.13. The consensus estimate for biote’s current full-year earnings is $0.75 per share. Roth Capital also issued estimates for biote’s Q2 2025 earnings at $0.12 EPS, Q3 2025 earnings at $0.15 EPS, Q4 2025 earnings at $0.16 EPS, FY2025 earnings at $0.53 EPS and FY2026 earnings at $0.70 EPS.

Separately, Craig Hallum decreased their target price on shares of biote from $12.00 to $8.00 and set a “buy” rating on the stock in a research note on Thursday.

biote Price Performance

BTMD opened at $3.07 on Friday. The company’s 50 day simple moving average is $5.01 and its two-hundred day simple moving average is $5.57. biote has a 1-year low of $3.04 and a 1-year high of $8.44. The firm has a market capitalization of $166.81 million, a price-to-earnings ratio of 11.81 and a beta of 1.07.

Institutional Trading of biote

Several institutional investors have recently made changes to their positions in BTMD. Victory Capital Management Inc. purchased a new stake in shares of biote during the 3rd quarter valued at approximately $106,000. MetLife Investment Management LLC raised its position in shares of biote by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 16,582 shares of the company’s stock valued at $93,000 after buying an additional 9,343 shares during the period. Wasatch Advisors LP raised its position in shares of biote by 8.4% during the 3rd quarter. Wasatch Advisors LP now owns 1,392,809 shares of the company’s stock valued at $7,772,000 after buying an additional 107,792 shares during the period. Jacobs Levy Equity Management Inc. raised its position in shares of biote by 24.9% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 272,377 shares of the company’s stock valued at $1,520,000 after buying an additional 54,302 shares during the period. Finally, Quarry LP purchased a new stake in shares of biote during the 3rd quarter valued at approximately $104,000. Hedge funds and other institutional investors own 21.68% of the company’s stock.

About biote

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.